Skip to main content

VERAXA Biotech AG (NASDAQ: VRXA) Advances VXA-222 Cancer Program Beyond Discovery Phase

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.
  • Following completion of the initial phase of its collaboration with OmniAb, VERAXA will engineer the final VXA-222 candidate and conduct the preclinical validation needed to determine the program’s next development steps.
  • VXA-222 uses an “AND-gate” approach designed to recognize two tumor-associated antigens simultaneously before delivering its therapeutic payload.
  • The company has separately filed its first patents related to its BiTAC-TCE and BiTAC-ADC platforms while expanding protection around antibody conjugation and payload technologies.
  • The company is building a diversified oncology pipeline spanning bispecific T-cell engagers, ADCs, and other engineered antibody formats.

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has moved its VXA-222 bispecific antibody-drug conjugate program into the next stage of development after completing the initial phase of its collaboration with OmniAb, giving the biotechnology company a new development milestone while it continues expanding the intellectual-property estate underpinning its antibody technology portfolio.

According to a Yahoo Finance report, VERAXA will now take the antibody binders generated through the OmniAb collaboration and use its own antibody engineering, linker and conjugation technologies to construct the final…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA

About BillionDollarClub

BillionDollarClub (“BDC”) is a specialized communications platform with a focus on the biggest and brightest companies covered by IBN. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BDC is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, BDC brings its clients unparalleled recognition and brand awareness.

BDC is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BillionDollarClub, text “Billion” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BillionDollarClub.com

Please see full terms of use and disclaimers on the BillionDollarClub website applicable to all content provided by BDC, wherever published or re-published: https://www.BillionDollarClub.com/Disclaimer

BillionDollarClub
Los Angeles, CA
www.BillionDollarClub.com
310.299.1717 Office
Editor@BillionDollarClub.com

BillionDollarClub is powered by IBN

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  262.96
+4.33 (1.67%)
AAPL  312.23
+2.88 (0.93%)
AMD  460.03
-13.22 (-2.79%)
BAC  62.05
+0.37 (0.59%)
GOOG  347.62
+5.87 (1.72%)
META  555.15
+5.25 (0.95%)
MSFT  489.13
+5.89 (1.22%)
NVDA  210.51
-4.21 (-1.96%)
ORCL  143.85
-2.62 (-1.79%)
TSLA  356.44
-6.42 (-1.77%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.